Summa Equity Fund II (“Summa”) has acquired a majority stake in G-CON, a leading US-based manufacturer of prefabricated cleanrooms used for manufacturing within the pharmaceuticals industry. G-CON designs, builds and installs turnkey cGMP (Current Good Manufacturing Practice) compliant suites called PODs, for a global biopharma customer base focused on biologics, pharma, CDMO (contract development and manufacturing), and cell and gene therapy manufacturing.
GlobalFoundries (GF), the global leader in feature-rich semiconductor manufacturing, today announced its expansion plans for its most advanced manufacturing facility in upstate New York over the coming years. These plans include immediate investments to address the global chip shortage at its existing Fab 8 facility as well as construction of a new fab on the same campus that will double the site’s capacity.
Freudenberg Medical, part of the Freudenberg Group and a global contract manufacturing partner to the medical device and pharmaceutical industry, has added a support team in India for customer sales and service to the region. Freudenberg is committed to serving medical device and pharmaceutical customers also present in Asia Pacific region with local operations in China and Singapore.
In our design, self-assembly of MOF nanoparticles and encapsulation of proteins are achieved simultaneously through a one-pot approach in aqueous environment. The enriched metal affinity sites on MOF surfaces act like the buttonhook, so the extracellular vesicle membrane can be easily buckled on the MOF nanoparticles.
Beyond Meat Triples Production Footprint with a new facility for Growing Demand Beyond Meat is opening a second...
Researchers uncovered a heterogeneous catalysis strategy that deliberately targets post-C-C coupling reaction intermediates during CO2 electrochemical reduction reaction. It opens avenues to the design of efficient catalysts that selectively produce higher-carbon liquid alcohols.
Velodyne LiDAR Brings World’s Most Advanced LiDAR Sensor. Adding the world’s most advanced LiDAR sensor to the Renovo AWare ecosystem provides fleet operators with the range, resolution and accuracy needed to guide autonomous vehicles reliably and safely through complex driving situations and conditions.
Using observations from NASA’s Hubble Space Telescope and ground-based observatories, an international team of scientists have confirmed ′Oumuamua, the first known interstellar object to travel through our solar system, got an unexpected boost in speed and shift in trajectory as it passed through the inner solar system last year.
Using graphene, one of science’s most versatile materials, engineers from the UCLA Samueli School of Engineering have invented a new type of photodetector that can work with more types of light than its current state-of-the-art counterparts. The device also has superior sensing and imaging capabilities.
ExoMars 2020 rover being pre-cleaned in an ultra-cleanroom environment in preparation for its sterilisation process, in an effort to prevent terrestrial microbes coming along for the ride to the red planet. Part of the Agency’s Life, Physical Sciences and Life Support Laboratory based in its Netherlands technical centre, This 35 sq. m ‘ISO Class 1’ cleanroom is one of the cleanest places in Europe.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has signed a definitive asset purchase agreement to acquire CTP-656 from Concert Pharmaceuticals (Nasdaq: CNCE). CTP-656 is an investigational cystic fibrosis transmembrane conductance regulator (CFTR) potentiator that has the potential to be used as part of future once-daily combination regimens of CFTR modulators that treat the underlying cause of cystic fibrosis (CF). As part of the agreement, Vertex will pay Concert $160 million in cash for all worldwide development and commercialization rights to CTP-656.
Researchers at Oregon State University and Oregon Health & Science University are working on a treatment that holds great promise for improving the lives of cystic fibrosis patients. Cystic fibrosis is a progressive genetic disorder that results in persistent lung infection and afflicts 30,000 people in the U.S., with about 1,000 new cases diagnosed every year.